Login
Evidence Feed
About
Diagnostics
New
FAQ
Contact us
^
Login
Contact us
to learn more about
our Premium Content: News alerts, weekly reports and conference planners
DRUG CLASS:
pan-HER inhibitor
DRUG CLASS:
pan-HER inhibitor
Contact us
to learn more about our Premium Content:
News alerts, weekly reports and conference planners
Related drugs:
‹
dacomitinib (32)
FCN-411 (4)
TAS2940 (4)
Z650 (2)
CI-1033 (1)
AC480 (0)
JRF103 (0)
dacomitinib (32)
FCN-411 (4)
TAS2940 (4)
Z650 (2)
CI-1033 (1)
AC480 (0)
JRF103 (0)
›
Associations
(45)
News
Trials
VERI cancer hierarchy
Reset Filters
EGFR L858R
Non Small Cell Lung Cancer
EGFR L858R
Non Small Cell Lung Cancer
dacomitinib
Sensitive: A1 - Approval
dacomitinib
Sensitive
:
A1
dacomitinib
Sensitive: A1 - Approval
dacomitinib
Sensitive
:
A1
EGFR exon 19 deletion
Non Small Cell Lung Cancer
EGFR exon 19 deletion
Non Small Cell Lung Cancer
dacomitinib
Sensitive: A1 - Approval
dacomitinib
Sensitive
:
A1
dacomitinib
Sensitive: A1 - Approval
dacomitinib
Sensitive
:
A1
EGFR mutation
Non Small Cell Lung Cancer
EGFR mutation
Non Small Cell Lung Cancer
dacomitinib
Sensitive: A1 - Approval
dacomitinib
Sensitive
:
A1
dacomitinib
Sensitive: A1 - Approval
dacomitinib
Sensitive
:
A1
EGFR L861Q
Non Small Cell Lung Cancer
EGFR L861Q
Non Small Cell Lung Cancer
dacomitinib
Sensitive: A2 - Guideline
dacomitinib
Sensitive
:
A2
dacomitinib
Sensitive: A2 - Guideline
dacomitinib
Sensitive
:
A2
EGFR S768I
Non Small Cell Lung Cancer
EGFR S768I
Non Small Cell Lung Cancer
dacomitinib
Sensitive: A2 - Guideline
dacomitinib
Sensitive
:
A2
dacomitinib
Sensitive: A2 - Guideline
dacomitinib
Sensitive
:
A2
EGFR G719X
Non Small Cell Lung Cancer
EGFR G719X
Non Small Cell Lung Cancer
dacomitinib
Sensitive: A2 - Guideline
dacomitinib
Sensitive
:
A2
dacomitinib
Sensitive: A2 - Guideline
dacomitinib
Sensitive
:
A2
EGFR G719A
Non Small Cell Lung Cancer
EGFR G719A
Non Small Cell Lung Cancer
dacomitinib
Sensitive: C2 – Inclusion Criteria
dacomitinib
Sensitive
:
C2
dacomitinib
Sensitive: C2 – Inclusion Criteria
dacomitinib
Sensitive
:
C2
EGFR overexpression
Esophageal Squamous Cell Carcinoma
EGFR overexpression
Esophageal Squamous Cell Carcinoma
Z650
Sensitive: C2 – Inclusion Criteria
Z650
Sensitive
:
C2
Z650
Sensitive: C2 – Inclusion Criteria
Z650
Sensitive
:
C2
HER-2 Y772_A775dup
Non Small Cell Lung Cancer
HER-2 Y772_A775dup
Non Small Cell Lung Cancer
dacomitinib
Sensitive: C3 – Early Trials
dacomitinib
Sensitive
:
C3
dacomitinib
Sensitive: C3 – Early Trials
dacomitinib
Sensitive
:
C3
HER-2 G778_P780dup
Non Small Cell Lung Cancer
HER-2 G778_P780dup
Non Small Cell Lung Cancer
dacomitinib
Sensitive: C3 – Early Trials
dacomitinib
Sensitive
:
C3
dacomitinib
Sensitive: C3 – Early Trials
dacomitinib
Sensitive
:
C3
HER-2 exon 20 insertion
Non Small Cell Lung Cancer
HER-2 exon 20 insertion
Non Small Cell Lung Cancer
dacomitinib
Sensitive: C3 – Early Trials
dacomitinib
Sensitive
:
C3
dacomitinib
Sensitive: C3 – Early Trials
dacomitinib
Sensitive
:
C3
HER-2 A775_G776insYVMA
Non Small Cell Lung Cancer
HER-2 A775_G776insYVMA
Non Small Cell Lung Cancer
dacomitinib
Sensitive: C3 – Early Trials
dacomitinib
Sensitive
:
C3
dacomitinib
Sensitive: C3 – Early Trials
dacomitinib
Sensitive
:
C3
^
^
×
Unlock More with VERI
Sign up to access premium content
Email *
Password *
Confirm Password *
I'm not a robot
Please register with your email ID.
×
Unlock More with VERI
Sign up to access premium content
Email *
Password *
Confirm Password *
I'm not a robot
Please register with your email ID.